On Tuesday, Repligen Corporation (NASDAQ:RGEN) purchased 908 Devices Inc.’s (NASDAQ:MASS) desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.
The purchase consideration is a payment of $70 million in cash. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for health and safety applications.
Adding these desktop assets complements and strengthens Repligen’s differentiated PAT portfolio, providing its biopharmaceutical and CDMO customers with insights to optimize development processes and improve manufacturing efficiencies.
Also Read: EVgo Stock Slides After Q4 EPS & Sales Miss Estimates
Products acquired from 908 Devices include MAVERICK and MAVEN for real-time monitoring and control of critical bioprocess parameters; REBEL, an at-line cell culture media analyzer; and ZipChip, a high-resolution sample separation device used to characterize product quality attributes.
Concurrently, 908 Devices reported fourth-quarter sales of $18.82 million, up 31% year over year, beating the consensus of $16.4 …
